Description
Tesamorelin | Stabilised GHRH Analogue — Research Grade
Tesamorelin is a synthetic analogue of GHRH in which a trans-3-hexenoic acid group is conjugated to the N-terminus to enhance metabolic stability. It is FDA-approved as Egrifta® for HIV-associated lipodystrophy, providing a robust clinical data foundation for further research.
Mechanism of Action
- Enhanced GHRH receptor binding — the hexenoic acid modification increases plasma half-life vs native GHRH
- GH pulse stimulation — preserves physiological pulsatility while increasing pulse amplitude
- Visceral fat reduction — Phase III RCTs demonstrated significant reduction in trunk fat vs placebo in lipodystrophy subjects
- IGF-1 normalisation — studied for restoration of IGF-1 levels in GH-deficient populations
Research Areas
Tesamorelin is studied in visceral adiposity, metabolic syndrome, cognitive function (IGF-1 CNS effects), and GH deficiency research. Clinical trial data from the EGRIFTA program provides an unusually strong evidence base.
For Research Use Only. Rainbow Peptide supplies Tesamorelin exclusively for in vitro and laboratory research purposes. Not for human or veterinary use.
Dr. V. Patel –
Tesamorelin used in our visceral adiposity research model. Purity confirmed 98.8% by our HPLC. IGF-1 pathway response in our in vitro assay tracked the published literature closely. Best-documented lot we’ve received.
C. Larsson –
Excellent Tesamorelin. Our GH axis model showed the expected GHRH-analogue response. COA includes full mass spec data confirming molecular weight. Cold-chain delivery was maintained. Will continue ordering.
B. Kamara –
Tesamorelin from Rainbow Peptide dissolved cleanly and behaved as expected in our assay. Purity >98%. The COA had good detail. Shipping was fast and temperature-controlled.